More MS news articles for February 2000

Fampridine-SR announcement

HAWTHORNE, N.Y., Feb. 14 /PRNewswire/ -- Acorda Therapeutics, Inc. will announce that it is beginning a late-stage, Phase 2 clinical trial of its lead product, Fampridine-SR, at the BIO CEO & Investor Conference in New York

Acorda's President and CEO, Ron Cohen, M.D., is scheduled to make a presentation at the conference on Wednesday, February 16, at 3:00 p.m.

The Company expects to begin the trial for chronic (long-term) spinal cord injury (SCI) in the first quarter of 2000.

Fampridine ("4-aminopyridine"; "4-AP") is a nerve conduction-enhancing compound that is the first therapy to improve neurological function in people with chronic SCI.

Fampridine-SR is a sustained-release oral tablet formulation developed by Acorda's corporate partner, the Elan Corporation plc.  The trial, which will be double-blind, randomized and placebo-controlled, will enroll 90 people
with chronic SCI at ten leading rehabilitation centers in the United States.

Fampridine-SR is also in Phase 2 clinical studies for multiple sclerosis (MS).  Prior clinical studies of Fampridine-SR have included over 130 people with chronic SCI and over 200 people with MS.

Patients in these trials showed improvement in a variety of functions.  Depending on the individual, these improvements have included enhanced bladder, bowel, and sexual function, increased ease of movement and sensation, and reduced muscle spasticity, fatigue and chronic pain.  Fampridine is not yet approved for any therapeutic use.

Ron Cohen, M.D., Acorda's President and CEO, said, "We are delighted to announce this latest milestone in the clinical development of Fampridine-SR. Currently, there is no therapy available that restores function to people with a long-term spinal cord injury.  Fampridine is not a cure, but it is a meaningful step forward.  To someone paralyzed from a spinal cord injury, regaining even a modest amount of control over their basic bodily functions, or reducing spasticity or pain, represents a huge improvement in their autonomy, their personal dignity, and their quality of life."

Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury and related neurological conditions, including multiple sclerosis.  In addition to Fampridine-SR, the Company's product pipeline includes M1, a human monoclonal antibody that has been shown to remyelinate the central nervous system in animal models, and is in preclinical development for multiple sclerosis.  Acorda is also developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain.

SOURCE Acorda Therapeutics, Inc.
Web Site: